Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Toggle navigation
Contact Us
Subscribe
Promote Your Event
e-Edition
Privacy Policy
Terms of Service
Local Weather
Home Delivery
Submission Forms
News
Local News
The Leader
Heartland News
Sports
Entertainment
Local Events
Multimedia
Photo Galleries
Videos
Obituaries
Classifieds
Real Estate
Property for Rent
Cars & Vehicles
Jobs
Items for Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place an ad
Legals
Best of 2022
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Actinium Pharmaceuticals Inc
(NY:
ATNM
)
8.670
UNCHANGED
Streaming Delayed Price
Updated: 8:00 PM EDT, Jun 8, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
8.670
Bid (Size)
8.130 (1)
Ask (Size)
9.500 (1)
Prev. Close
8.670
Today's Range
8.670 - 8.670
52wk Range
4.670 - 15.12
Shares Outstanding
21,331,314
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
(ATNM) - Analyzing Actinium Pharmaceuticals's Short Interest
March 09, 2023
Via
Benzinga
Actinium Pharma Cratered 37% Over Two Days — Here's Why, According To CEO Sandesh Seth
February 24, 2023
Actinium CEO Sandesh Seth says the tumble this week had little to do with clinical data.
Via
Investor's Business Daily
Performance
YTD
-13.47%
-13.47%
1 Month
+2.73%
+2.73%
3 Month
-6.27%
-6.27%
6 Month
-21.54%
-21.54%
1 Year
+60.56%
+60.56%
More News
Read More
Global Market for Acute Myeloid Leukemia Expected to Reach $3.2 Billion By 2029
February 22, 2023
Via
FinancialNewsMedia
Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia
February 22, 2023
Via
FinancialNewsMedia
Actinium Shares Are Trading Higher After Positive Data From Acute Myeloid Leukemia Trial
October 31, 2022
Via
Benzinga
With Upcoming Pivotal Data, Analyst Sees 145% Upside In Actinium
September 08, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
February 21, 2023
Via
Benzinga
What's Going On With Actinium Pharmaceuticals Stock?
February 21, 2023
Via
Benzinga
Why Owlet Shares Are Trading Higher By Over 45%; Here Are 20 Stocks Moving Premarket
February 21, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
February 21, 2023
Via
InvestorPlace
Actinium Pharmaceuticals’ Shares Stay Bullish Ahead Of Expected Topline Phase 3 Data Release In Q4 ($ATNM)
December 12, 2022
Via
AB Newswire
Actinium Pharmaceuticals’ Shares Rally Ahead Of Topline Phase 3 Data Release; Update Expected By Year’s End ($ATNM)
December 08, 2022
Via
AB Newswire
Dollar Tree, Dycom Industries, Chico's FAS And Other Big Losers From Tuesday
November 23, 2022
Via
Benzinga
Why American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From Yesterday
November 23, 2022
Via
Benzinga
Why Dollar Tree Shares Are Trading Lower By 10%? Here Are 53 Stocks Moving In Tuesday's Mid-Day Session
November 22, 2022
Via
Benzinga
4 Analysts Have This to Say About Actinium Pharmaceuticals
October 31, 2022
Via
Benzinga
Why Is Getty Images (GETY) Stock Up 33% Today?
October 31, 2022
Via
InvestorPlace
Why Sonnet BioTherapeutics Shares Surged Over 66%; Here Are 63 Biggest Movers From Yesterday
November 01, 2022
Via
Benzinga
PERF Stock Soars 21% on First Trading Day
October 31, 2022
Via
InvestorPlace
Actinium (ATNM) Stock Pops on Positive Trial Results
October 31, 2022
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
October 31, 2022
Via
InvestorPlace
Actinium Pharmaceuticals’ Q4 Phase 3 Trial Updates Could Make Expected Milestones 2023 Catalysts ($ATNM)
October 26, 2022
Via
AB Newswire
Actinium Pharmaceuticals’ Investor Update Puts Clinical Milestones And Potential Catalysts In The Crosshairs ($ATNM)
October 24, 2022
Via
AB Newswire
Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2022
September 08, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
August 25, 2022
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.